Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk expects China to approve Wegovy this year
11:34am, Thursday, 07'th Mar 2024
Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes.
Novo's global obesity drug rollout to be dominated by injectable medicines, CEO says
11:25am, Thursday, 07'th Mar 2024
Novo Nordisk's global obesity drug rollout will be dominated by its injectable medicines, while its oral version will be introduced later in higher priced markets, the company's Chief Executive Lars F
Pharma Stock Hits Record High on Newest Weight-Loss Drug
11:20am, Thursday, 07'th Mar 2024
Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin.
Novo Nordisk Surges. It's on Track to Overtake Tesla's Market Cap.
11:16am, Thursday, 07'th Mar 2024
The company said its new treatment for weight loss, called Amycretin, appeared even more effective than its popular Wegovy drug in trials.
Wegovy Maker Novo Nordisk Stock Surges on Promising Trial of Obesity Pill Amycretin
11:05am, Thursday, 07'th Mar 2024
The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained more than 8% in early trading Thursday after the Danish maker of Ozempic and Wegovy released promising data on an experimenta
Novo Nordisk expects Catalent deal to close later this year
10:31am, Thursday, 07'th Mar 2024
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is see
Ozempic Maker Novo Nordisk More Valuable Than Tesla
10:11am, Thursday, 07'th Mar 2024
Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss trea
NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug
09:21am, Thursday, 07'th Mar 2024
Novo Nordisk (NYSE: NVO ) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial. The big news here is the company's oral weight
Novo Nordisk obesity pill results send shares to record high
08:44am, Thursday, 07'th Mar 2024
Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming blockbuster drug Wegovy. An early-s
Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial
07:00am, Thursday, 07'th Mar 2024
Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company's plans to cement its prime position in
Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips
06:22am, Thursday, 07'th Mar 2024
Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.
Novo Nordisk to present early-stage trial data for new diabetes drug at investor meeting
02:11am, Thursday, 07'th Mar 2024
Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
09:36am, Wednesday, 06'th Mar 2024
Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
05:50am, Wednesday, 06'th Mar 2024
Investors are excited about the opportunity for Viking's experimental weight-loss drug VK2735. Viking doesn't compare favorably against Lilly and Novo Nordisk in most categories.
Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday
06:23pm, Tuesday, 05'th Mar 2024
A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.
